ardx-202309250001437402false00014374022023-09-252023-09-250001437402dei:OtherAddressMember2023-09-252023-09-25
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 25, 2023
ARDELYX, INC.
(Exact name of registrant as specified in its charter)
| | | | | | | | |
Delaware | 001-36485 | 26-1303944 |
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification Number) |
400 FIFTH AVE., SUITE 210, WALTHAM, MASSACHUSETTS 02451
(Address of principal executive offices, including Zip Code)
Registrant’s telephone number, including area code: (510) 745-1700
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| | | | | |
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| | | | | | | | | | | | | | |
Title of each class | | Trading Symbol(s) | | Name of each exchange on which registered |
Common Stock, par value $0.0001 | | ARDX | | The Nasdaq Global Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 8.01 Other Events.
On September 25, 2023, Ardelyx, Inc. (the “Company”) announced that its collaboration partner in Japan, Kyowa Kirin Co., Ltd. (TSE: 4151, Kyowa Kirin), has received approval from the Japanese Ministry of Health, Labour and Welfare for the new drug application for tenapanor for the improvement of hyperphosphatemia in adult patients with chronic kidney disease on dialysis.
This approval triggers an aggregate of $30 million from Kyowa Kirin to the Company in milestone payments and payments under the recent amendment to the license agreement between the Company and Kyowa Kirin. As a result of this approval, the Company will also receive a $5 million payment under the terms of its agreement with HealthCare Royalty Partners. In addition, the Company may also receive an additional $5 million from HealthCare Royalty Partners in the event net sales in Japan exceed a certain target by 2025.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
| | | | | | | | |
Exhibit No. | | Description |
104 | | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | | | | |
Date: September 25, 2023 | ARDELYX, INC. |
| | |
| By: | /s/ Justin Renz |
| | Justin Renz |
| | Chief Financial and Operations Officer |